XOMA Added to the Russell 2000® and Russell 3000® Indexes
EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to […]
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBDIND […]
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of […]
Resonant Inc. to Join Russell 2000® and 3000® Indexes
GOLETA, Calif., June 29, 2020 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, […]
TSX News -
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AMLPhase 1a/b study in B-cell malignancies continues […]
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and […]
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and […]
GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
CARLSBAD, Calif., June 29, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic […]
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected EnrollmentCompletion of Trial Enrollment Anticipated Early Third Quarter […]
Ultralife Corporation Announces Addition to the Russell 2000® Index
NEWARK, N.Y., June 29, 2020 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) today announced it has been added to the […]
